Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. More...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancers (Basel)
Hoofdauteurs: Hofman, Paul, Badoual, Cécile, Henderson, Fiona, Berland, Léa, Hamila, Marame, Long-Mira, Elodie, Lassalle, Sandra, Roussel, Hélène, Hofman, Véronique, Tartour, Eric, Ilié, Marius
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI 2019
Onderwerpen:
Review
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468415/
https://ncbi.nlm.nih.gov/pubmed/30818873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030283
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items